Center-Authored Papers

Filters: Author is Schenk, Jeannette M  [Clear All Filters]
2008
Dong LM, Kristal AR, Peters U, Schenk JM, Sanchez CA, Rabinovitch PS, Blount PL, Odze RD, Ayub K, Reid BJ et al..  2008.  Dietary supplement use and risk of neoplastic progression in esophageal adenocarcinoma: a prospective study.. Nutrition and cancer. 60(1):39-48. Abstract
Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Goodman P, Penson DF, Thompson IM.  2008.  Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.. American journal of epidemiology. 167(8):925-34. Abstract
Kristal AR, Schenk JM, Song YJ, Arnold KB, Neuhouser ML, Goodman PJ, Lin DW, Stanczyk FZ, Thompson IM.  2008.  Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial.. American journal of epidemiology. 168(12):1416-24. Abstract
2009
Schenk JM, Riboli E, Chatterjee N, Leitzmann MF, Ahn J, Albanes D, Reding DJ, Wang Y, Friesen MD, Hayes RB et al..  2009.  Serum retinol and prostate cancer risk: a nested case-control study in the prostate, lung, colorectal, and ovarian cancer screening trial.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 18(4):1227-31. Abstract
Framson C, Kristal AR, Schenk JM, Littman AJ, Zeliadt S, Benitez D.  2009.  Development and validation of the mindful eating questionnaire.. Journal of the American Dietetic Association. 109(8):1439-44. Abstract
Gong Z, Kristal AR, Schenk JM, Tangen CM, Goodman PJ, Thompson IM.  2009.  Alcohol consumption, finasteride, and prostate cancer risk: results from the Prostate Cancer Prevention Trial.. Cancer. 115(16):3661-9. Abstract
Schenk JM, Neuhouser ML, Lin DW, Kristal AR.  2009.  A dietary intervention to elicit rapid and complex dietary changes for studies investigating the effects of diet on tissues collected during invasive surgical procedures.. Journal of the American Dietetic Association. 109(3):459-63. Abstract
Schenk JM, Kristal AR, Neuhouser ML, Tangen CM, White E, Lin DW, Thompson IM.  2009.  Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial.. The Prostate. 69(12):1303-11. Abstract
2010
Beasley JM, Schenk JM, Ludman E, Lampe JW, Reed SD, Grothaus L, Newton KM.  2010.  Brief telephone intervention increases soy intake in peri- and postmenopausal US women: the Herbal Alternatives Trial (HALT).. Journal of the American Dietetic Association. 110(8):1189-97. Abstract
Schenk JM, Kristal AR, Neuhouser ML, Tangen CM, White E, Lin DW, Kratz M, Thompson IM.  2010.  Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.. American journal of epidemiology. 171(5):571-82. Abstract
Kristal AR, Price DK, Till C, Schenk JM, Neuhouser ML, Ockers S, Lin DW, Thompson IM, Figg WD.  2010.  Androgen receptor CAG repeat length is not associated with the risk of incident symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial.. The Prostate. 70(6):584-90. Abstract
2011
Schenk JM, Kristal AR, Arnold KB, Tangen CM, Neuhouser ML, Lin DW, White E, Thompson IM.  2011.  Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial.. American journal of epidemiology. 173(12):1419-28. Abstract
2012
Schenk JM, Calip GS, Tangen CM, Goodman P, Parsons KJ, Thompson IM, Kristal AR.  2012.  Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.. American journal of epidemiology. 176(2):156-63. Abstract
Parsons KJ, Schenk JM, Arnold KB, Messer K, Till C, Thompson IM, Kristal AR.  2012.  Finasteride Reduces the Risk of Incident Clinical Benign Prostatic Hyperplasia.. European urology. Abstract
2013
Schenk JM, Hunter-Merrill R, Zheng Y, Etzioni R, Gulati R, Tangen C, Thompson IM, Kristal AR.  2013.  Should Modest Elevations in Prostate-Specific Antigen, International Prostate Symptom Score, or Their Rates of Increase Over Time be Used as Surrogate Measures of Incident Benign Prostatic Hyperplasia? American journal of epidemiology. Abstract
2014
Kristal AR, Till CA, Song X, Tangen CM, Goodman PJ, Neuhouser ML, Schenk JM, Thompson IM, Meyskens FL, Goodman GE et al..  2014.  Plasma Vitamin D and Prostate Cancer Risk; Results from the Selenium and Vitamin E Cancer Prevention Trial.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. Abstract
Schenk JM, Till CA, Tangen CM, Goodman PJ, Song X, Torkko KC, Kristal AR, Peters U, Neuhouser ML.  2014.  Serum 25-hydroxyvitamin d concentrations and risk of prostate cancer: results from the prostate cancer prevention trial.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 23(8):1484-93. Abstract
2015
Chau CH, Price DK, Till C, Goodman PJ, Chen X, Leach RJ, Johnson-Pais TL, Hsing AW, Hoque A, Tangen CM et al..  2015.  Finasteride concentrations and prostate cancer risk: results from the prostate cancer prevention trial.. PloS one. 10(5):e0126672. Abstract
Nash SH, Schenk JM, Kristal AR, Goodman PJ, Lucia SM, Parnes HL, Thompson IM, Lippman SM, Song X, Gurel B et al..  2015.  Association between serum phospholipid fatty acids and intraprostatic inflammation in the placebo arm of the Prostate Cancer Prevention Trial.. Cancer prevention research (Philadelphia, Pa.). Abstract
Patel DP, Schenk JM, Darke A, Myers JB, Brant WO, Hotaling JM.  2015.  Non-steroidal Anti-inflammatory Drug use Not Associated with Erectile Dysfunction Risk: Results from the Prostate Cancer Prevention Trial.. BJU international. Abstract
Barrington WE, Schenk JM, Etzioni R, Arnold KB, Neuhouser ML, Thompson IM, Lucia SM, Kristal AR.  2015.  Difference in Association of Obesity With Prostate Cancer Risk Between US African American and Non-Hispanic White Men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT).. JAMA oncology. 1(3):342-9. Abstract
Key TJ, Appleby PN, Travis RC, Albanes D, Alberg AJ, Barricarte A, Black A, Boeing H, Bueno-de-Mesquita BH, Chan JM et al..  2015.  Carotenoids, retinol, tocopherols, and prostate cancer risk: pooled analysis of 15 studies.. The American journal of clinical nutrition. 102(5):1142-57. Abstract
2016
Price DK, Chau CH, Till C, Goodman PJ, Leach RJ, Johnson-Pais TL, Hsing AW, Hoque A, Parnes HL, Schenk JM et al..  2016.  Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial.. Cancer. 122(15):2332-2340. Abstract
Tangen CM, Goodman PJ, Till C, Schenk JM, Lucia SM, Thompson IM.  2016.  Biases in Recommendations for and Acceptance of Prostate Biopsy Significantly Affect Assessment of Prostate Cancer Risk Factors: Results From Two Large Randomized Clinical Trials.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(36):4338-4344. Abstract
Schenk JM, Till C, Hsing AW, Stanczyk FZ, Gong Z, Neuhouser ML, Reichardt JK, Hoque AM, Figg WD, Goodman PJ et al..  2016.  Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial.. Cancer causes & control : CCC. 27(2):175-182. Abstract